About Method Made: The Tech Transfer Edge in Cell & Gene Therapy
In Cell & Gene Therapy, opportunity created by openly discussing operational reality far outweighs the micro-risk of looking unpolished. By building a safe, unscripted space where experts can talk naturally about real work, we stop pretending everything is fine and start building the solutions needed to actually fix the system.
Explore our Solution: https://www.methodmade.ca/?utm_source=podcast&utm_medium=show_notes&utm_campaign=out_of_the_lab
Restoring Patient Agency: Breaking the 80% Access Barrier in Cell Therapy | Michelle Hill
In this episode of Out of the Lab, host Nico Crudele sits down with Michelle Hill, a 30-year biotech veteran, Kite Gilead alum and founder of Avenue to Care, to examine why revolutionary cell therapies like CAR T are failing to reach over 80% of eligible patients.
Michelle breaks down the severe non-clinical, operational, and socioeconomic barriers keeping advanced treatments locked behind elite academic medical centers. From community physician referral gaps and geographic attrition to building data-neutral care orchestration platforms, this conversation explores how the industry can bridge the gap between treatment availability and true patient access.
Key Takeaways:
Why CAR T adoption has plateaued at 20% and how current access disproportionately favors patients with health literacy and financial means.
How general oncologists' lack of familiarity with cell therapy risks and successes creates early patient drop-outs.
The role of non-clinical care orchestration in restoring patient agency without crossing pharma compliance boundaries.
Navigating post-treatment survivorship, long-term follow-up registry demands (CIBMTR), and the impact of REMS updates on patient travel requirements.
Timestamps & Key Topics:
00:00:00 – Introduction & Method Made Sponsor
00:01:16 – The 80% Access Deficit & Infrastructure Gaps
00:03:32 – The 10-Mile Rule & Geographic Attrition
00:06:26 – Early Diagnoses & The Loss of Patient Agency
00:11:32 – Rare Disease, Autoimmune, and the CAR T Horizon
00:14:07 – General Oncologist Referral Hesitancy & Perceived Failures
00:17:03 – Socioeconomic Privilege in Clinical Access
00:22:17 – Introducing Avenue to Care: Public Benefit Care Orchestration
00:26:34 – Post-Treatment Care, Survivorship, & Long-Term Data Tracking
00:31:07 – Global Access Challenges & Health Literacy
00:35:12 – Rebuilding Healthcare Around the Patient
29 Sept 2026
The 2 AM Audit Reality: Ex-FDA Regulators on CDMO Oversight, Night Shift Sins, and Data Integrity
Why do processes that look clean on paper collapse during an FDA inspection?
In this episode of Out of the Lab, host Nico Crudele sits down with ex-FDA auditors DeVaughn Edwards (GMP specialist) and Elvia Cervantes (GCP specialist) to break down the most common and preventable compliance disasters in cell and gene therapy.
From night-shift compliance breakdowns and paper-only CDMO audits to data manipulation and informal quality decisions, DeVaughn and Elvia share unvarnished insights from their time inside the agency and in the field.
Key Takeaways:
You Can't Outsource Liability: Why delegating manufacturing to a CDMO or clinical monitoring to a CRO does not clear a sponsor's regulatory responsibility.
The "Boots on the Ground" Mandate: Why paper questionnaires fail vendor qualification and how unmonitored night shifts breed compliance failures.
Building Code vs. Blueprint: The cost of bringing Quality teams in midstream rather than from project inception.
Data Integrity Realities: What actual record destruction and email-based decision-making signal to FDA investigators.
Modern Audit Readiness: How remote regulatory assessments (RRAs), 1-day audits, and AI tools like ELSA are changing FDA oversight.
Timestamps / Show Notes:
00:01:16 – The cost of involving Quality teams too late in development.
00:05:29 – Qualifying CDMOs: Why "boots on the ground" beat paper questionnaires.
00:09:08 – The 2 AM reality check: Night shift compliance breakdowns.
00:14:00 – Modern audit readiness, 1-day inspections, and FDA’s ELSA system.
00:24:43 – Data integrity red flags: Document destruction and pressure-driven cover-ups.
00:41:33 – Operational silos: When administrative assistants make escalation decisions.
00:47:32 – What an effective CAPA actually looks like.
01:05:15 – Inspecting emails and server migrations as regulatory liabilities.
22 Sept 2026
The $1M CDMO Selection Trap & Rethinking CMC Roadmaps with Shri Joshi
Why does selecting the cheapest CDMO quote often lead to millions of dollars in unexpected costs down the road?
In this episode of Out of the Lab, host Nico sits down with industry veteran Shri Joshi, who has navigated cell and gene therapy operations across consulting, CDMO, and sponsor sides to break down the core ingredients of a successful drug development lifecycle.
We explore why CDMO selection must be treated as a development and risk-management decision rather than a simple procurement task. Shri breaks down why early investments in analytical methods create crucial operational flexibility, why the adage "the process is the product" can actually harm development, and how early-stage founders can build a true "comparability mindset" to de-risk clinical progression.
Key Topics Covered:
00:01:34 – The 3 core ingredients of cell & gene therapy development
00:04:20 – Why CDMO selection is a risk management decision, not procurement
00:07:28 – Case Study: Transparency vs. unrealistic timeline promises
00:18:38 – The real cost of cheap contracts: How a $1M discount cost $5M later
00:21:41 – CMC 101: Chemistry, Manufacturing, & Controls explained
00:24:37 – Why "the process is the product" dogma creates operational bottlenecks
00:27:53 – Developing analytical methods early to enable comparability
00:32:04 – Utilizing Quality Target Product Profiles (QTPP) & Process Flow Diagrams
This episode is brought to you by Method Made. Accelerate your tech transfer by up to six months using video SOPs to capture technical nuance. Download the free Tech Transfer Failure Modes and Effects Analysis at methodmade.ca by clicking Download FMEA.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Spotify
4.0 / 5
2 ratings
Contact Method Made: The Tech Transfer Edge in Cell & Gene Therapy
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Method Made: The Tech Transfer Edge in Cell & Gene Therapy?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
